Skip to main content

Lee Yuchun's Form 4 filing

Vertex Pharmaceuticals Inc (VRTX) · filed Apr 12, 2022

Accession no.
0000899243-22-014551
Filed
Apr 12, 2022
Trade date
Apr 8-11, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 9 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.12M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lee YuchunCIK 0001334365Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 8, 2022Common StockMOption exerciseAcquired+2,000$81.54+$163,0803,875Direct
Apr 8, 2022Common StockSSaleDisposed−418$276.62F2,F3−$115,627.163,457Direct
Apr 8, 2022Common StockSSaleDisposed−430$277.29F2,F4−$119,234.73,027Direct
Apr 8, 2022Common StockSSaleDisposed−700$279.36F2,F5−$195,5522,327Direct
Apr 8, 2022Common StockSSaleDisposed−452$280.37F2,F6−$126,727.241,875Direct
Apr 11, 2022Common StockMOption exerciseAcquired+2,000$81.54+$163,0803,875Direct
Apr 11, 2022Common StockSSaleDisposed−922$279.81F2,F7−$257,984.822,953Direct
Apr 11, 2022Common StockSSaleDisposed−968$280.62F2,F8−$271,640.161,985Direct
Apr 11, 2022Common StockSSaleDisposed−110$281.58F2,F9−$30,973.81,875Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Apr 8, 2022Common StockMOption exerciseDisposed−2,000$0.00$010,000Direct
Apr 11, 2022Common StockMOption exerciseDisposed−2,000$0.00$08,000Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Referenced by the price of 7 transactions in Table I.

F3

Open market sales reported on this line occurred at a weighted average price of $276.62 (range $276.08 to $276.81).

Referenced by the price of 1 transaction in Table I.

F4

Open market sales reported on this line occurred at a weighted average price of $277.29 (range $277.16 to $277.46).

Referenced by the price of 1 transaction in Table I.

F5

Open market sales reported on this line occurred at a weighted average price of $279.36 (range $278.86 to $279.74).

Referenced by the price of 1 transaction in Table I.

F6

Open market sales reported on this line occurred at a weighted average price of $280.37 (range $280.06 to $281.02).

Referenced by the price of 1 transaction in Table I.

F7

Open market sales reported on this line occurred at a weighted average price of $279.81 (range $279.29 to $280.18).

Referenced by the price of 1 transaction in Table I.

F8

Open market sales reported on this line occurred at a weighted average price of $280.62 (range $280.31 to $281.28).

Referenced by the price of 1 transaction in Table I.

F9

Open market sales reported on this line occurred at a weighted average price of $281.58 (range $281.55 to $281.58).

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)